This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble...

This dataset contains summary data visualizations and clinical data from a broad 183 samples of thoracic tumors from 77 patients. The data was generated by the Charles Rudin Lab, utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, patient demographics,...

This dataset contains summary data visualizations and clinical data from a broad sampling of 1,661 samples of across multiple cancer types showing tumor mutational load and survival following immunotherapy from 1,661 patients. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK),...

This dataset contains summary data visualizations and clinical data from 67 samples from 67 patients as part an NCI-60 cell line project to compile NCI-60 cell line high-throughput and high-content data into CellMiner, a genomic and pharmacologic database created by the National Cancer Center Institute. The clinical data includes deidentified patient and sample IDs, mutation counts, detailed cancer...

Summary from the GEO: "Immune checkpoint blockade (ICB) has demonstrated significant promise for the treatment of advanced malignancies. Anti-CTLA4 and ant-PD1 therapy can activate the immune system and result in durable control in diseases such as melanoma and non-small cell lung cancer. 109 RNASeq samples (58 On-treatment and 51 Pre-treatment) from 65 patients." Abstract from the publication that...

This dataset contains the summary data visualizations and clinical data of targeted sequencing of 248 samples from 124 patients' cfDNA/WBC[White Blood Cell] and tumor/normal pairs. Clinical data includes: Cancer Type, Mutation Count, Age, Tumor Type, cfDNA TMB, Collapsed fragment mean coverage, Collapsed mean coverage, ctDNA Fraction, MSI Score, Oncotree Code, cfDNA/Tumor Sample Class, Tumor Tissue...

This dataset contains the summary data visualizations and clinical data from targeted sequencing of 915 samples from 860 patients with metastatic lung adenocarcinoma. Clinical data includes: Number of Samples Per Patient, Mutation Count, Fraction Genome Altered, Diagnosis Age, Sex, Primary/Metastasis Sample Type, Chemotherapy, Clinical Trial, Driver Mutations, Durable Clinical Benefit, Gene Panel,...

This dataset contains the summary data visualizations and clinical data from whole-exome sequencing of 75 tumor/normal NSCLC pairs treated with PD-1 plus CTLA-4 blockade from 75 patients. Clinical data includes: Mutation Count, Sex, Histology, Age (yrs), Best Overall Response, Durable Clinical Benefit, ECOG performance status, HLA_A1 allele, HLA_A2 alleles, HLA_B1 alleles, HLA_B2 alleles, HLA_C1 alleles,...

This dataset contains the summary data visualizations and clinical data from IMPACT sequencing of 240 NSCLC tumor/normal pairs treated at MSKCC with anti-PD-(L)1 based therapy from 240 patients. Clinical data includes: Cancer Type, Mutation Count, Fraction Genome Altered, Sex, Durable Clinical Benefit, FGA, Gene Panel, IRB, Lines of treatment, Mutation Rate, Oncotree Code, PD-L1 Score (%), Smoker,...

Summary from the GEO: "Success of immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) has invigorated their use in neo-adjuvant setting for early-stage disease. However, the cellular and molecular mechanisms of the early immune responses to therapy remain poorly understood. Through an integrated analysis of early-stage NSCLC patients and a Kras-mutant mouse model, we show a...